

<b>INFORMATION DISCLOSURE CITATION</b> Form PTO-1449 (Modified) <i>(Use several sheets if necessary)</i>	<b>ATTY. DOCKET NO.</b> UCSF-085 CIP	<b>SERIAL NO.</b> 09/616,223
	<b>APPLICANT</b> Nadel et al.	
	<b>FILING DATE</b> July 14, 2000	<b>GROUP</b> 1635 Unassigned

### U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
J3	AN	5,525,625	06/11/96	Bridges et al.			
J3	AO	6,037,361	03/14/00	Roth et al.			

### FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
J3	AP	WO 97/19065	05/29/97	PCT				
J3	AQ	WO 97/45412	12/04/97	PCT				
	AR	WO 98/37881	09/03/98	PCT				
	AS	WO 99/01421	01/14/99	PCT				
	AT	WO 99/01426	01/14/99	PCT				
	AU	WO 99/32121	07/01/99	PCT				
	AV	WO 00/06560	02/10/00	PCT				
	AW	WO 00/06561	02/10/00	PCT				
	AX	WO 00/09485	02/24/00	PCT				
	AY	WO 00/17162	03/30/00	PCT				


### OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

J3	AA	Donato et al (1989), "Tumor Necrosis Factor Modulates Epidermal Growth Factor Receptor Phosphorylation and Kinase Activity in Human Tumor Cells", <i>The Journal of Biological Chemistry</i> , Vol. 264(34): 20474-20481.
J3	AB	Desseyn et al. (1997), "Human Mucin Gene MUC5B, the 10.7-kb Large Central Exon Encodes Various Alternate Subdomains Resulting in a Super-repeat", <i>The Journal of Biological Chemistry</i> , Vol. 272(6): 3168-3178.

<b>EXAMINER</b> J3	<b>DATE CONSIDERED</b> 3-2-07
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>INFORMATION DISCLOSURE CITATION</b> Form PTO-1449 (Modified) <i>(Use several sheets if necessary)</i>		<b>ATTY. DOCKET NO.</b> UCSF-085 CIP	<b>SERIAL NO.</b> 09/616,223
		<b>APPLICANT</b> Nadel et al.	
		<b>FILING DATE</b> July 14, 2000	<b>GROUP</b> 1635 Unassigned
83	AC	Goldstein et al. (1995), "Biological Efficacy of a Chimeric Antibody to the Epidermal Growth Factor Receptor in a Human Tumor Xenograft Model", <i>Clinical Cancer Research</i> , Vol. 1: 1311-1318.	
	AD	Kawamoto et al. (1983), "Growth stimulation of A431 cells by epidermal growth factor: Identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 80: 1337-1341.	
	AE	Kondapaka et al. (1996), "Tyrosine kinase inhibitor as a novel signal transduction and antiproliferative agent: prostate cancer", <i>Molecular and Cellular Endocrinology</i> , Vol. 117: 53-58.	
	AF	Levitski (1994), "Signal-transduction therapy, a novel approach to disease management", <i>Eur. J. Biochem.</i> , Vol. 226(1):1-13.	
	AG	Lorimer, et al. (1995), "Immunotoxins that Target an Oncogenic Mutant Epidermal Growth Factor Receptor Expressed in Human Tumors", <i>Clinical Cancer Research</i> , Vol. 1: 859-864.	
	AH	Petit et al. (1997), "Neutralizing Antibodies against Epidermal Growth Factor and ErbB-2/neu Receptor Tyrosine Kinases Down-Regulate Vascular Endothelial Growth Factor Production by Tumor Cells <i>in Vitro</i> and <i>in Vivo</i> ", <i>American Journal of Pathology</i> , Vol. 151(6): 1523-1530.	
	AI	Powis (1994), "Signaling pathways as targets for anticancer drug development", <i>Pharmac. Ther.</i> , Vol. 62:57-95.	
	AJ	Schmidt et al. (1996), "Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF $\alpha$ ", <i>British Journal of Cancer</i> , Vol. 74: 853-862.	
	AK	Takeyama et al. (1998), "Neutrophil-dependent goblet cell degranulation: role of membrane-bound elastase and adhesion molecules", <i>Am. J. Physiol.</i> , Vol. 275:294-302.	
	AL	Temann et al. (1997), "A Novel Role for Murine IL-4 <i>In Vivo</i> : Induction of MUC5AC Gene Expression and Mucin Hypersecretion", <i>Am J. Respir. Cell Biol.</i> , Vol. 16:471-478.	
	AM	Ullrich et al. (1984), "Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells." <i>Nature</i> , Vol. 309(5967):418-25.	
	AZ	Brown (1999), "Clinical Studies with matrix metalloproteinase inhibitors." <i>APMIS</i> , Vol. 107:174-180.	
	BA	Grandis, jr., et al. (1997), "Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells." <i>Oncogene</i> , Vol. 15(4):409-416.	
	BB	Kumar et al. (1998), "Cooperative interaction of autocrine and paracrine mitogens for airway epithelial cells." <i>Cell Biology and Toxicology</i> , Vol. 14(4):293-299.	
	BC	Lee et al. (2000), "Leukotriene Receptor Antagonists and Synthesis Inhibitors Reverse Survival in Eosinophils of Asthmatic Individuals." <i>American Journal of Respiratory and Critical Care Medicine</i> , Vol. 161(6):1881-1886.	
	BD	Prenzel et al. (1999), "EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF." <i>Nature</i> , Vol. 402:884-888.	
	BE	Takeyama et al. (1999), "Epidermal growth factor system regulates mucin production in airways." <i>Proceedings of the national Academy of Sciences USA</i> , Vol. 96(6):3081-3086.	
	BF	Takeyama et al. (2000), "Oxidative stress causes mucin synthesis via transactivation of epidermal growth factor receptor: role of neutrophils." <i>Journal of Immunology</i> , Vol. 164(3):1546-1552.	
	BG	Wojtowicz-Praga et al. (1997), "Matrix metalloproteinase inhibitors." <i>Investigational New Drugs</i> . Vol. 15:61-75.	

F:\forms\word 2k forms\form PTO-1449.doc

<b>EXAMINER</b> 	<b>DATE CONSIDERED</b> 3-2-07
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>SUPPLEMENTAL INFORMATION DISCLOSURE CITATION</b> Form PTO-1449 (Modified) (Use several sheets if necessary)	ATTY. DOCKET NO. UCSF-085CIP	SERIAL NO. 09/616,223
	APPLICANT Nadel, et al.	
	FILING DATE July 14, 2000	GROUP Unassigned

### U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

### FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

### OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

93	AA	Grandis et al. (July 24, 1997), "Inhibition of Epidermal Growth Factor Receptor Gene Expression and Function Decreases Proliferation of Head and Neck Squamous Carcinoma but not Normal Mucosal Epithelial Cells." <i>Oncogene</i> , Vol. 15(4):406-416
----	----	---

EXAMINER 93	DATE CONSIDERED 3-2-07
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/616,223
		Filing Date	July 14, 2000
		First Named Inventor	Nadel, et al.
		Group Art Unit	1614
		Examiner Name	Zara, Jane
Sheet	1	of	1
		Attorney Docket Number	UCSF-085CIP

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.†	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code* (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.†	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Office*	Number*	Kind Code* (if known)				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		†
		GUZMAN, et al. "Epidermal growth factor regulates expression of the mucous phenotype of rat tracheal epithelial cells", <i>Biochem. Biophys. Res. Com.</i> , (1995) Vol. 217(2): 412-418.		

Examiner Signature		Date Considered	3-2-07
-----------------------	--	--------------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Unique citation designation number. †Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	09/616,223	
			Filing Date	July 14, 2000	
			First Named Inventor	NADEL, JAY A.	
			Art Unit	1635	
			Examiner Name	ZARA, JANE	
Sheet	1	of	1	Attorney Docket Number	UCSF-085CIP

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)				
J3		US- 5,559,111 (HU P9501230A)		09-24-1996	Guschke	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS							
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)					

Examiner Signature	J3	Date Considered	3-2-07
-----------------------	----	--------------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<b>SUPPLEMENTAL INFORMATION DISCLOSURE CITATION</b> Form PTO-1449 (Modified) <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO. UCSF085CIP		SERIAL NO. 09/616,223	
				APPLICANT Nadel et al.			
				FILING DATE July 14, 2000		GROUP 1614 1635	
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Date	Country	Class	Subclass	Translation
83	AA	WO 00/10588 A3	03/02/2000	PCT			Yes      No
<b>OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							

F:\DOCUMENT\UCSF085cip\Supp.Form PTO-1449.doc

<b>EXAMINER</b> 83-	<b>DATE CONSIDERED</b> 3-2-07
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10816159
	Filing Date		2004-03-31
	First Named Inventor	Jay A. NADEL	
	Art Unit	1635	
	Examiner Name	Jane J. Zara	
	Attorney Docket Number	UCSF-085CON5	

## U.S. PATENTS

Remove

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
83	1	6551989	B2	2003-04-22	NADEL et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

## U.S. PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

## FOREIGN PATENT DOCUMENTS

Remove

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
83	1	760766	AU	B2	2000-03-14	NADEL et al.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

## NON-PATENT LITERATURE DOCUMENTS

Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>


**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10816159
Filing Date	2004-03-31
First Named Inventor	Jay A. NADEL
Art Unit	1635
Examiner Name	Jane J. Zara
Attorney Docket Number	UCSF-085CON5

	1		<input type="checkbox"/>
--	---	--	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature		Date Considered	3-2-07
--------------------	---	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.





PTO/SB/08a (05-03)


Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>			
		Application Number	10/816.159		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Filing Date	March 31, 2004		
		First Named Inventor	NADEL, JAY A.		
		Art Unit	1615 1635		
		Examiner Name	To Be Assigned		
Sheet	1	of	2	Attorney Docket Number	UCSF-085CON5

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)				
		US- 5,116,616		05-26-1992	Bio-Technology General Corp.	
		US- 5,760,041		06-02-1998	American Cyamid Company	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
		WO 96/09294 A1	03-28-1996	The Well-Come Foundation Limited		
		WO 92/18481	10-29-1992	Rhone-Poulenc Rorer International, Inc.		
		DE 4117078 A1	11-26-1992	Boehringer Ingelheim KG		X
		DE 1792207	11-04-1971	Fisons Pharmacuetciuals Ltd.		

Examiner Signature		Date Considered	3-2-07
-----------------------	--	--------------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/816,159
		Filing Date	March 31, 2004
		First Named Inventor	NADEL, JAY A
		Group Art Unit	1814 7635
		Examiner Name	To Be Assigned
Sheet 2 of 2	Attorney Docket Number	UCSF-085CON5	

OTHER ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
J3		Van Herwaarden et al., "The role of N-acetylcysteine in the treatment of chronic obstructive pulmonary disease." Netherlands Journal of Medicine, 47 (1995): 45-48	
J3		Amishma, M. et al., "Expression of epidermal growth factor and epidermal growth factor receptor immunoreactivity in the asthmatic human airway.: American Journal of Respiratory and Critical Care medicine, Vol. 157, No. 6, June 1998, pgs. 1907-1912	

Examiner Signature	J3	Date Considered	3-2-07
--------------------	----	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.